PD-1/PD-L1
PD-1/Programmed death-ligand 1
Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.
PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.
All Product Categories
-
PD-1/PD-L1 Inhibitors
(343)
View all products
-
PD-1/PD-L1 Agonists
(5)
View all products
-
PD-1/PD-L1 Antagonists
(11)
View all products
-
PD-1/PD-L1 Activators
(16)
View all products
-
PD-1/PD-L1 Modulators
(7)
View all products
-
PD-1/PD-L1 Inducers
(3)
View all products
-
PD-1/PD-L1 Degraders
(13)
View all products
-
PD-1/PD-L1 Control
(1)
View all products
-
PD-1/PD-L1 Substrates
(2)
View all products
-
PD-1/PD-L1 Ligands
(7)
View all products
-
PD-1/PD-L1 Related Products (453)
Related Products (453)
-
Antibodies (8)
-
PD-1/PD-L1-IN-9 hydrochloride
0 ImagesCat. No.: HY-132192APurity: 98.59%PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model.
-
Pucotenlimab
0 ImagesCat. No.: HY-P99938CAS No.: 2403647-03-8Synonyms: HX008Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor.
-
Biotin-itaconate
0 ImagesCat. No.: HY-185447CAS No.: 3086566-93-7
-
Emfizatamab
0 ImagesCat. No.: HY-P99914CAS No.: 2559704-23-1Synonyms: GNC-038Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia.
-
Fidasimtamab
0 ImagesCat. No.: HY-P99618CAS No.: 2377419-89-9Synonyms: IBI-315; BH2950Fidasimtamab is a bispecific antibody targeting human epidermal growth factor receptor 2 (Her2) and programmed death protein 1 (PD-1), with a Ka of 3.55e-10 M for human Her2 and a Ka of 1.17e-9 M for human PD-1. Fidasimtamab cross-links Her2-positive tumor cells with PD-1-positive T cells to form immune synapses, blocks PD-1-ligand interactions, preserves antibody-dependent cellular cytotoxicity, induces gasdermin B (GSDMB)-mediated pyroptosis, and activates T cells. Fidasimtamab is applicable to relevant research on Her2-positive gastric cancer.
-
Naamidine J
0 ImagesNaamidine J is an imidazole-type alkaloids discovered in a sponge. Naamidine J inhibits inflammation by binding to the protein CSE1L (KD = 5.41 μM). Namidine J significantly inhibits the expression of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, and upregulates anti-inflammatory factors such as CD206 and Arg-1. Namidine J inhibits PD-L1 and shows antitumor activity. Namidine J significantly reduces pulmonary tissue edema, inflammatory cell infiltration and cytokine storm in mice. Namidine J can be used for the research on the immune microenvironment of acute lung injury and tumors.
-
Rilvegostomig
0 ImagesSynonyms: AZD-2936Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer.
-
Enristomig
0 ImagesSynonyms: ES-101; INBRX-105
-
Safimestomig
0 ImagesSynonyms: 6MW3211
-
Besufetamig
0 ImagesSynonyms: ONO-4685Besufetamig is a bispecific antibody targeting programmed cell death 1 (PD-1) and CD3ε chain. Besufetamig modulates the activity of immune cells, exerting immunosuppressive and antineoplastic activities. Besufetamig is promising for research of cancers.
-
PD-1/PD-L1-IN-42
0 ImagesCat. No.: HY-P10217Purity: 99.82%PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC50 of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy.
-
PD-1/PD-L1-IN-13
0 ImagesPD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC50 value of 10.2 nM. PD-1/PD-L1-IN-13 promots CD8+ T cell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse model.
-
Garivulimab
0 ImagesSynonyms: BGB-A333
-
Itanistomig
0 ImagesCat. No.: HY-P991004CAS No.: 2923687-56-1Synonyms: LB-101Itanistomig (LB-101) is a tetravalent bispecific antibody targeting PD-L1 and CD47. Itanistomig blocks PD-L1 and achieves tumor enrichment through binding to PD-L1, and also exerts conditional CD47 blocking activity via cleavage of the hinge linker in the PD-L1-positive tumor microenvironment. Itanistomig induces antibody-dependent cellular phagocytosis in human CD14+ cells and drives tumor regression. Itanistomig can be used in research related to solid tumors.
-
PD-1/PD-L1-IN-10
0 ImagesPD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy.
-
Pimivalimab
0 ImagesCat. No.: HY-P99887CAS No.: 2293951-22-9Synonyms: JTX-4014Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor.
-
PD-1/PD-L1-IN-NP19
0 ImagesPD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects.
-
Sudubrilimab
0 ImagesSynonyms: HS636Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment.
